Oragenics, Inc. (OGEN)

NYSEAMERICAN: OGEN · Real-Time Price · USD
0.314
+0.017 (5.76%)
Nov 4, 2024, 3:59 PM EST - Market closed
5.76%
Market Cap 3.53M
Revenue (ttm) 7,466
Net Income (ttm) -19.52M
Shares Out 11.26M
EPS (ttm) -6.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 135,700
Open 0.286
Previous Close 0.297
Day's Range 0.286 - 0.314
52-Week Range 0.280 - 7.740
Beta 0.48
Analysts n/a
Price Target n/a
Earnings Date Nov 15, 2024

About OGEN

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibioti... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 5
Stock Exchange NYSEAMERICAN
Ticker Symbol OGEN
Full Company Profile

Financial Performance

In 2023, Oragenics's revenue was $37,653, a decrease of -71.37% compared to the previous year's $131,521. Losses were -$20.66 million, 44.6% more than in 2022.

Financial Statements

News

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be present...

17 days ago - GlobeNewsWire

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

SARASOTA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, today provided ...

26 days ago - GlobeNewsWire

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

SARASOTA, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, has completed a key study fo...

27 days ago - GlobeNewsWire

Oragenics, Inc. Announces Closing of Public Offering

SARASOTA, Fla., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders...

2 months ago - GlobeNewsWire

Oragenics, Inc. Announces Pricing of Public Offering

SARASOTA, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders...

2 months ago - GlobeNewsWire

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

• Falls and car accidents lead incidence of concussions in emergency departments • Spray-dried drug formulation allows for easy delivery to patients • No pharmaceutical treatment is available for conc...

2 months ago - GlobeNewsWire

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

SARASOTA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurolo...

2 months ago - GlobeNewsWire

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

• ONP-002 stability eliminates need for cumbersome cold storage • No FDA-approved pharmaceutical treatment available for concussion

2 months ago - GlobeNewsWire

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

– ONP-002 showed no cancer-causing DNA damage – Phase II clinical trial being planned SARASOTA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on deve...

3 months ago - GlobeNewsWire

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globally The potential addressable market opportunity for ONP-002 includes an estimated 69 million...

3 months ago - GlobeNewsWire

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders,...

4 months ago - GlobeNewsWire

Oragenics, Inc. Announces Proposed Public Offering

SARASOTA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal pharmaceuticals for the treatment of n...

4 months ago - GlobeNewsWire

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Dr. Peacock to Oversee Upcoming Phase II Clinical Trial for Treating Concussion in the Emergency Department Dr. Peacock to Oversee Upcoming Phase II Clinical Trial for Treating Concussion in the Emerg...

5 months ago - GlobeNewsWire

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

SARASOTA, Fla., May 17, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today anno...

6 months ago - GlobeNewsWire

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced ...

7 months ago - Business Wire

Oragenics, Inc. Files 10K and Provides Company Update

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (the “Company”) (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, ...

7 months ago - Business Wire

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced ...

8 months ago - Business Wire

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced ...

8 months ago - Business Wire

Oragenics Announces Closing of Public Offering

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment...

8 months ago - Business Wire

Oragenics Announces Pricing of Public Offering

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment...

8 months ago - Business Wire

Oragenics Announces Proposed Public Offering

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment...

8 months ago - Business Wire

Oragenics, Inc. Announces Leadership Transition

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurologica...

9 months ago - Business Wire

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, tod...

9 months ago - Business Wire

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, tod...

9 months ago - Business Wire

Oragenics Announces Termination of At-The-Market Offering Program

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has terminated its previously announced “at-the-market” (“ATM”) equity offering pr...

10 months ago - Business Wire